News Image

Why the dividend investor may take a look at NASDAQ:GILD.

By Mill Chart

Last update: Apr 17, 2024

Our stock screener has singled out GILEAD SCIENCES INC (NASDAQ:GILD) as a promising choice for dividend investors. NASDAQ:GILD not only scores well in profitability, solvency, and liquidity but also offers a decent dividend. We'll explore this further.

Dividend Assessment of NASDAQ:GILD

ChartMill provides a Dividend Rating for every stock, ranging from 0 to 10. This rating assesses various dividend aspects, including yield, growth, and sustainability. NASDAQ:GILD earns a 7 out of 10:

  • With a Yearly Dividend Yield of 4.49%, GILD is a good candidate for dividend investing.
  • GILD's Dividend Yield is rather good when compared to the industry average which is at 19.20. GILD pays more dividend than 99.15% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 2.39, GILD pays a better dividend.
  • GILD has been paying a dividend for at least 10 years, so it has a reliable track record.
  • As GILD did not decrease their dividend in the past 5 years, we can say the dividend looks stable.

How We Gauge Health for NASDAQ:GILD

To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NASDAQ:GILD has earned a 5 out of 10:

  • The Altman-Z score of GILD (2.58) is better than 73.50% of its industry peers.
  • GILD has a debt to FCF ratio of 3.37. This is a good value and a sign of high solvency as GILD would need 3.37 years to pay back of all of its debts.
  • GILD has a Debt to FCF ratio of 3.37. This is amongst the best in the industry. GILD outperforms 95.38% of its industry peers.

Profitability Analysis for NASDAQ:GILD

ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:GILD, the assigned 7 is a significant indicator of profitability:

  • With an excellent Return On Assets value of 9.12%, GILD belongs to the best of the industry, outperforming 97.09% of the companies in the same industry.
  • With an excellent Return On Equity value of 24.81%, GILD belongs to the best of the industry, outperforming 98.12% of the companies in the same industry.
  • The Return On Invested Capital of GILD (12.07%) is better than 97.27% of its industry peers.
  • GILD has a better Profit Margin (20.89%) than 97.61% of its industry peers.
  • Looking at the Operating Margin, with a value of 28.23%, GILD belongs to the top of the industry, outperforming 98.12% of the companies in the same industry.
  • GILD has a Gross Margin of 76.04%. This is amongst the best in the industry. GILD outperforms 85.64% of its industry peers.

Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.

Our latest full fundamental report of GILD contains the most current fundamental analsysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.



NASDAQ:GILD (5/24/2024, 7:00:00 PM)

After market: 65.25 -0.43 (-0.65%)


-0.49 (-0.74%)


News Image5 days ago - InvestorPlace3 Biotech Stocks to Buy Now: May 2024

As the biotech industry continues to rise in market prominence, investors should start considering what the best biotech stocks to buy are.

News Image5 days ago - Gilead Sciences, Inc.Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
News Image6 days ago - Zacks Investment ResearchHere is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock

Recently, users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

News Image8 days ago - PRLogThe P3 App: Empowering and Elevating Underprivileged Youth from Socioeconomically Disadvantaged Areas Through Innovative Mentorship

CHICAGO - May 18, 2024 - PRLog -- The Pulse of Perseverance alongside Gilead is proud to announce the launch of the P3 mobile app, a pioneering platform unveiled at our signature benefit event on May 16, now available on the app store. Designed to transform the landscape of mentorship, the P3 app connects students from underprivileged backgrounds with mentors in underrepresented fields, fostering a supportive community and opening doors to internships and career opportunities.Amidst the backdrop of systemic barriers that often hinder the academic and professional aspirations of Black children, the P3 app stands as a beacon of hope and opportunity. It not only bridges the gap in resource access but also challenges the status quo by providing a direct funnel to success in advanced fields where youth from socioeconomically disadvantaged areas are vastly underrepresented.Features of the P3 App:

News Image9 days ago - Gilead Sciences, Inc.Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
News Image10 days ago - InvestorPlacePenny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch

Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns.

News Image12 days ago - Market News VideoSee Which Of The Latest 13F Filers Holds Gilead Sciences
News Image13 days ago - Gilead Sciences, Inc.Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
News Image13 days ago - Yahoo FinanceOne stock is dragging down the S&P 500's earnings growth

S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.

News Image17 days ago - Gilead Sciences, Inc.Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
News Image18 days ago - InvestorPlaceBiotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine

These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.

News Image18 days ago - ChartmillWhy NASDAQ:GILD qualifies as a good dividend investing stock.

Why GILEAD SCIENCES INC (NASDAQ:GILD) is a Top Pick for Dividend Investors.

GILD Links
Follow us for more